Preparation method and application of CAR-T (Chimeric Antigen Receptor-T) cell loaded with biological calcified nanomaterial
By preparing BCLT, a biocalcified nanomaterial with mitochondrial targeting on its surface, and linking it to CAR-T cells, the problems of poor infiltration effect and immunosuppressive microenvironment of CAR-T cells in solid tumor treatment were solved, achieving highly efficient tumor killing and infiltration effects, and improving treatment efficacy and mouse survival rate.
Patent Information
- Application Number
- CN202610257658.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-04
- Publication Date
- 2026-05-29
AI Technical Summary
CAR-T cell therapy for solid tumors suffers from poor infiltration, an acidic immunosuppressive microenvironment in the tumor, insufficient target specificity, and issues related to carrier toxicity and biocompatibility. Existing biomaterial carrier delivery systems cannot effectively improve the immunosuppressive microenvironment and have insufficient targeting efficiency.
Using a biocalcified nanomaterial (BCLT) preparation method, black phosphorus quantum dots, calcium peroxide and lipid components are mixed, ultrasonically emulsified and purified by ultrafiltration centrifugation to prepare BCLT with mitochondrial targeting molecules on the surface. These BCLTs are then linked to the surface of CAR-T cells via disulfide bonds, enabling the release of black phosphorus quantum dots after tumor cell endocytosis to promote oxidative phosphorylation, improve the immunosuppressive microenvironment, and achieve precise delivery by combining mitochondrial targeting and chemical bond stability.
In in vitro experiments, CAR-T cells loaded with biocalcified nanomaterials significantly improved the killing effect and tumor spheroid infiltration capacity. In in vivo experiments, the tumor infiltration capacity and therapeutic effect were the best, improving the survival rate of mice and alleviating the problem of tumor heterogeneity of CAR-T cells.